Blog
RSS FeedPosted by Michael Wonder on 06 Sep 2022
COVID-19: a global opinion on bivalent vaccines in mid-September
5 September 2022 - The EMA has just modified the marketing authorisations granted to messenger RNA vaccines developed by Moderna and ...
Posted by Michael Wonder on 02 May 2022
HAS clarifies the framework for use of Xevudy
29 April 2022 - After authorising early access to Xevudy (sotrovimab) as a curative treatment for COVID-19 on 6 January, HAS ...
Posted by Michael Wonder on 26 Apr 2022
HAS decides in favour of reimbursement of Paxlovid
25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed ...
Posted by Michael Wonder on 19 Mar 2022
COVID-19: a second booster reserved for those most at risk
18 March 2022 - While the COVID-19 epidemic seems to be on the rise again after a few weeks of decline, ...
Posted by Michael Wonder on 22 Jan 2022
COVID-19: early access granted to Paxlovid as a curative treatment
21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the ...
Posted by Michael Wonder on 15 Dec 2020
Vaccination strategy against SARS-Cov-2
15 December 2020 - Intermediate recommendations on the methods of implementing vaccination. ...
Posted by Michael Wonder on 04 Dec 2020
COVID-19 vaccine will be free of charge, 1 million inoculations set for January, French PM say
3 December 2020 - After the vaccination of an initial 1 million people in January an additional 14 million at ...